TEAM In 'team' TEAMCancer Research UK Clinical Trials Unit (CRCTU) TEAM: An open label randomised multicentre comparative trial of 5 years adjuvant exemestane treatment versus adjuvant tamoxifen followed by exemestane in postmenopausal women with early stage breast cancer Chief Investigator: Dr Daniel Rea Sponsor: University of Birmingham Funder: Pfizer Disease Site: Breast Cancer Trial Type: Clincial Trial of an Investigational Medicinal Product Status: In Follow-up UKCRN Study ID (if applicable): 2004218974GB ISRCTN Referance Number: 75225940 Open to New Sites? No Recruitment Start Date: 05-Dec-2001 Recruitment End Date: 07-Oct-2005 CRCTU Trial Management Team: Late Phase Trial Management Team- B Trial Email Address: team@trials.bham.ac.uk Trial Summary The TEAM trial was designed in 2000/2001 and was originally designed to compare tamoxifen for 5 years with exemestane for 5 years in postmenopausal women with early breast cancer. A large body of information regarding third-generation aromatase inhibitors in early breast cancer emerged and in particular data was published following the start of recruitment, which demonstrated a clear Relapse Free Survival (RFS) advantage to a sequential strategy in which exemestane is introduced after 2-3 years of prior tamoxifen. As a result of this data an amendment to the trial design was introduced in which patients originally randomised to tamoxifen were recommended to switch to exemestane after 2.5-3 years of tamoxifen therapy. All patients, regardless of whether or not they switched treatment, were followed up for 10 years. Please note that the trials team cannot give individual’s clinical advice. Patients and their families should contact their treating physician to discuss trials for which they may be eligible. View Trial Inclusion/Exclusion Criteria Document Trial Protocol View Trial Protocol Document Please Note:Clinical trial protocols are complex technical documents which should only be used for the treatment of subjects taking part in the trial.Investigators please ensure you have R&D approval for this specific version of the protocol before using as a reference. Other Websites CancerHelp (Cancer Research)